Search Result

Results for "

GPX4+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ACSL Family (1) ADC Payload (1) Apoptosis (1) DNA/RNA Synthesis (1) Drug-Linker Conjugates for ADC (1) Ferroptosis (23) Glutathione Peroxidase (25) Lipoxygenase (1) PROTACs (1) Reactive Oxygen Species (ROS) (7) Reference Standards (1) Transferrin Receptor (1)
By Research Areas:	Cancer (25) Inflammation/Immunology (1) Neurological Disease (1)
Click Chemistry:	Azide (1) Alkynes (4)

Inhibitors & Agonists

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100002

ML162 10+ Cited Publications	Glutathione Peroxidase Ferroptosis	Cancer
ML162 is a covalent glutathione peroxidase 4 (GPX4) inhibitor. ML162 has a selective lethal effect on mutant RAS oncogene-expressing cell lines

HY-100003

ML-210 Maximum Cited Publications 29 Publications Verification	Glutathione Peroxidase Ferroptosis	Cancer
ML-210 is a selective and covalent glutathione peroxidase 4 (GPX4) inhibitor with an EC₅₀ of 30 nM. ML-210 binds the GPX4 selenocysteine residue. ML-210 has anti-cancer activity .

HY-138153

JKE-1674 5+ Cited Publications	Glutathione Peroxidase Ferroptosis	Cancer
JKE-1674 is an orally active glutathione peroxidase 4 (GPX4) inhibitor and an active metabolite of *GPX4* inhibitor ML-210. JKE-1674, an analog of ML-210 in which the nitroisoxazole ring is replaced with an α-nitroketoxime. JKE-1674 can convert into a nitrile oxide JKE-1777. JKE-1674 kills LOX-IMVI cells in a manner that is equipotent to ML-210 and is completely rescued by ferroptosis inhibitors .

HY-141809

GPX4-IN-3 2 Publications Verification	Glutathione Peroxidase Ferroptosis	Cancer
GPX4-IN-3 (26a) is a potent glutathione peroxidase 4 (GPX4) inhibitor as a selective ferroptosis inducer. GPX4-IN-3 (26a) exhibits 71.7% inhibition for GPX4 with 1 μM .

HY-175615

RSL3-NH2	ADC Payload Glutathione Peroxidase Ferroptosis	Cancer
RSL3-NH2 is a *GPX4* inhibitor and ferroptosis inducer. RSL3-NH2 triggers the iron-dependent cell death pathway associated with lipid peroxidation by inhibiting GPX4 activity. RSL3-NH2 exhibits significant cytotoxicity against colorectal cancer cells and effectively induces their ferroptosis. RSL3-NH2 can serve as a ADC payload for synthesizing antibody-drug conjugates (ADC) and be used in colorectal cancer-related research .

HY-115701

1-Stearoyl-2-15(S)-Hpete-Sn-Glycero-3-Pe 1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-phosphoethanolamine; 15(S)-HpETE-SAPE; 15(S)-hydroperoxyeicostetraenoic acid-SAPE	Ferroptosis	Inflammation/Immunology
1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-Pe is a phospholipid that contains stearic acid (HY-B2219) at the sn-1 position and 15(S)-HpETE at the sn-2 position. It is produced via oxidation of 1-stearoyl-2-arachidonoyl-sn-glycero-3-Pe (SAPE) by 15-lipoxygenase (15-LO). 1-Stearoyl-2-15(S)-HpETE-sn-glycero-3-Pe (0.6 and 0.9 μM) increases ferroptotic cell death in wild-type and Acsl4 knockout Pfa1 mouse embryonic fibroblasts (MEFs) treated with the GPX4 inhibitor RSL3.

HY-149923

GPX4-IN-4	Glutathione Peroxidase	Cancer
GPX4-IN-4 (Compound 24) is a potent *GPX4* inhibitor. GPX4-IN-4 can be used for the research of cancer .

HY-139001

JKE-1716	Glutathione Peroxidase Ferroptosis	Others
JKE-1716 is a potent and selective nitrolic acid-containing *GPX4* inhibitor. JKE-1716 is able of inducing ferroptosis selectively through covalent *GPX4* inhibition .

HY-167888

NPD4928	Ferroptosis Glutathione Peroxidase	Cancer
NPD4928, a *GPX4* inhibitor, enhances RSL3 (HY-100218A)-dependent ferroptosis. NPD4928 binds to ferroptosis suppressor protein 1 (FSP1) and inhibits its enzymatic activity .

HY-178364

GPX4-IN-19	Glutathione Peroxidase Ferroptosis Lipoxygenase Reactive Oxygen Species (ROS) DNA/RNA Synthesis	Cancer
GPX4-IN-19 is an effective *GPX4* inhibitor (IC₅₀ = 0.311 μM), covalently binds to the Sec 46 site of GPX4. GPX4-IN-19 shows strong anti-proliferative activity with high ferroptosis selectivity. GPX4-IN-19 causes intracellular Fe ²⁺ accumulation, leading to increased levels of lipid peroxides (LPOs) and reactive oxygen species (ROS), which induces ferroptosis and subsequently results in DNA damage. GPX4-IN-19 can be used for the study of Triple-Negative Breast Cancer (TNBC) .

HY-157762

GPX4-IN-9	Glutathione Peroxidase Ferroptosis	Cancer
GPX4-IN-9 (Compound A16) is a glutathione peroxidase 4 (GPX4) inhibitor that specifically targets *GPX4* under both in vitro and in vivo conditions, inducing ferroptosis. GPX4-IN-9 exhibits cytotoxicity against pancreatic cancer cells and can be used in cancer research .

HY-153748

ML162-yne	Glutathione Peroxidase	Cancer
ML162-yne is a potent GPX4-inhibitor affinity probe . ML162-yne is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-175614

RSL3-NH2-Ala-Val-DBCO-PEG4-Maleimide	Drug-Linker Conjugates for ADC Glutathione Peroxidase Ferroptosis	Cancer
RSL3-NH2-Ala-Val-DBCO-PEG4-Maleimide is a drug-linker conjugate for ADC. RSL3-NH2-Ala-Val-DBCO-PEG4-Maleimide consists of a *GPX4* inhibitor and ferroptosis inducer (RSL3-NH2) (HY-175615) and a linker (H-Ala-Val-OH) (HY-P4955). RSL3-NH2-Ala-Val-DBCO-PEG4-Maleimide can be used for synthesis of ADCs .

HY-34765

Propiolamide	Glutathione Peroxidase Reactive Oxygen Species (ROS) Ferroptosis Apoptosis	Cancer
Propiolamide is a monooxygenase (MMO) system activator and glutathione peroxidase 4 (GPX4) inhibitor. Propiolamide induces ROS production through interaction with the MMO system. Propiolamide promotes the accumulation of intracellular cytotoxic lipid peroxides and induces ferroptosis. Propiolamide induces programmed cell death via the apoptosis pathway. Propiolamide can be used in cancer research .

HY-149455

GPX4-IN-8	Glutathione Peroxidase	Cancer
GPX4-IN-8 (compound A80) is a potent *GPX4* inhibitor. GPX4-IN-8 shows antiproliferative activity .

HY-175633

ML210-ansaFc	Glutathione Peroxidase Ferroptosis Reactive Oxygen Species (ROS)	Cancer
ML210-ansaFc (Compound III-13) is a covalent GPX4 inhibitor with a -ferrocenophane group (IC₅₀ of 3.4 μM). ML210-ansaFc potently induces ferroptosis by increasing the level of ROSand promoting lipid peroxidation (LPO) in cancers cells. ML210-ansaFc has an anticancer activity and suppresses tumor growth in tumor 3D spheroids. ML210-ansaFc can be used for cancer therapy resistance research .

HY-179384

PROTAC FSP1 degrader 1	ACSL Family PROTACs Ferroptosis Glutathione Peroxidase Transferrin Receptor Reactive Oxygen Species (ROS)	Cancer
PROTAC FSP1 degrader 1 is a highly efficient and selective PROTAC degrader targeting FSP1. PROTAC FSP1 degrader 1 significantly induces the accumulation of intracellular lipid peroxides. PROTAC FSP1 degrader 1 exhibits synergistic induction of ferroptosis with GPX4 inhibitors. PROTAC FSP1 degrader 1 can induce ROS production. PROTAC FSP1 degrader 1 upregulates the mRNA expression of ferroptosis-related proteins (GPX4, FTH1, ACSL4, TfR1, FSP1). PROTAC FSP1 degrader 1 can be used for the study of triple-negative breast cancer .

HY-162718

GPX4-IN-12	Ferroptosis	Cancer
GPX4-IN-12 (compound I22) is a non-covalent *GPX4* inhibitor. GPX4-IN-12 induces ferroptosis and inhibits cell growth of HT1080 cells .

HY-162716

GPX4-IN-10	Ferroptosis	Cancer
GPX4-IN-10 (compound I20) is a non-covalent *GPX4* inhibitor. GPX4-IN-10 induces ferroptosis and inhibits cell growth of HT1080 cells .

HY-168879

GPX4-IN-16	Glutathione Peroxidase	Cancer
GPX4-IN-16 ((R)-9i) is a potent *GPX4* inhibitor with an K_d value of 20.4 nM. GPX4-IN-16 shows cytotoxicity. GPX4-IN-16 shows anticancer activity .

HY-163995

GPX4-IN-13	Ferroptosis Glutathione Peroxidase	Cancer
GPX4-IN-13 (compound 16) is a *GPX4* inhibitor with anticancer activity. GPX4-IN-13 reduces thyroid cell proliferation and induces ferroptosis by inhibiting the expression level of *GPX4. GPX4-IN-13* inhibits the growth of three thyroid cancer cell lines: N-thy-ori-3-1 (IC₅₀=8.39 μM), MDA-T32 (IC₅₀=10.28 μM) and MDA-T41 (IC₅₀=8.18 μM) .

HY-138544

GPX4-IN-1	Glutathione Peroxidase	Cancer
GPX4-IN-1 is a potent *GPX4* inhibitor. GPX4 shows antiproliferative activity. GPX4-IN-1 has the potential for the research of cancer .

HY-181447

GPX4 (S)-9i	Glutathione Peroxidase Ferroptosis	Cancer
GPX4 (S)-9i is a *GPX4* inhibitor and ferroptosis inducer, with its (R) enantiomer exhibiting stronger activity. GPX4 (S)-9i can be used for the study of fibrosarcoma .

HY-186143

KY0418	Glutathione Peroxidase Ferroptosis	Cancer
KY0418 is a selective *GPX4* inhibitor. KY0418 selectively and covalently modifies the selenocysteine residue of GPX4 and inhibits GPX4 activity. KY0418 induces ferroptosis and suppresses cell proliferation. KY0418 can be used for the study of ferroptosis and cancer .

HY-100002R

ML162 (Standard)	Glutathione Peroxidase Reference Standards Ferroptosis	Cancer
ML162 (Standard) is the analytical standard of ML162 (HY-100002). This product is intended for research and analytical applications. ML162 is a covalent glutathione peroxidase 4 (GPX4) inhibitor. ML162 has a selective lethal effect on mutant RAS oncogene-expressing cell lines

HY-182072

GPX4-IN-23	Glutathione Peroxidase Ferroptosis Reactive Oxygen Species (ROS)	Neurological Disease
GPX4-IN-23 (Compound 3e) is a *GPX4* inhibitor with an IC₅₀ of 0.27 μM. GPX4-IN-23 induces Ferroptosis by enhancing lipid peroxidation, ROS production, and intracellular GSH depletion. GPX4-IN-23 exhibits antiproliferative activity against central nervous system cancer cells. GPX4-IN-23 can be used in studies related to central nervous system cancers .

HY-183294

GPX4-IN-24	Glutathione Peroxidase Ferroptosis Reactive Oxygen Species (ROS)	Cancer
GPX4-IN-24 is an orally active glutathione peroxidase 4 (GPX4) inhibitor with a human IC₅₀ of 10.90 μM, human K_d of 10.04 μM. GPX4-IN-24 suppresses GPX4 enzymatic activity, disrupts redox homeostasis, drives lipid peroxidation, promotes lipid peroxidation, and induces ferroptosis. GPX4-IN-24 can be used for the research of triple-negative breast cancer .

HY-180199

GPX4-IN-21	Glutathione Peroxidase Ferroptosis Reactive Oxygen Species (ROS)	Cancer
GPX4-IN-21 (Compound 4d) is a selective glutathione peroxidase 4 (GPX4) inhibitor. GPX4-IN-21 can induce ferroptosis and downregulate the ferroptosis-related proteins SLC7A11, SLC11A2 and *GPX4* levels. GPX4-IN-21 can induce ROS and MDA accumulation GPX4-IN-21 exhibits potent anti-proliferative activity. GPX4-IN-21 can be used for the research of cancer, such as melanoma .

Cat. No.	Product Name		Classification

HY-153748

ML162-yne		Alkynes
ML162-yne is a potent GPX4-inhibitor affinity probe . ML162-yne is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-175633

ML210-ansaFc		Alkynes
ML210-ansaFc (Compound III-13) is a covalent GPX4 inhibitor with a -ferrocenophane group (IC₅₀ of 3.4 μM). ML210-ansaFc potently induces ferroptosis by increasing the level of ROSand promoting lipid peroxidation (LPO) in cancers cells. ML210-ansaFc has an anticancer activity and suppresses tumor growth in tumor 3D spheroids. ML210-ansaFc can be used for cancer therapy resistance research .

HY-168879

GPX4-IN-16		Azide
GPX4-IN-16 ((R)-9i) is a potent *GPX4* inhibitor with an K_d value of 20.4 nM. GPX4-IN-16 shows cytotoxicity. GPX4-IN-16 shows anticancer activity .

HY-138544

GPX4-IN-1		Alkynes
GPX4-IN-1 is a potent *GPX4* inhibitor. GPX4 shows antiproliferative activity. GPX4-IN-1 has the potential for the research of cancer .

HY-181447

GPX4 (S)-9i		Alkynes
GPX4 (S)-9i is a *GPX4* inhibitor and ferroptosis inducer, with its (R) enantiomer exhibiting stronger activity. GPX4 (S)-9i can be used for the study of fibrosarcoma .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.